News & Media
Company News
-
Atlas Molecular Pharma at BIO-Europe 2026 in Cologne
→: Atlas Molecular Pharma at BIO-Europe 2026 in CologneAtlas Molecular Pharma will be at BIO-Europe 2026, held November 9-11 in Cologne. CEO Susana Castel and Business Development Manager Luis Ruiz-Avila…
-
First three patients with CEP dosed with ATL-001
→: First three patients with CEP dosed with ATL-001We are proud to announce that on October 19, 2026, the first three patients with Congenital Erythropoietic Porphyria (CEP) enrolled in the ATL001-PII-CEP clinical trial received…
-
Atlas Molecular Pharma at BIO-Europe Spring 2026
→: Atlas Molecular Pharma at BIO-Europe Spring 2026Atlas Molecular Pharma will be attending BIO-Europe Spring 2026, starting March 23. CEO Susana Castel and Business Development Manager Luis Ruiz-Avila will participate in the event as we…
-
First patients enrolled in Atlas Molecular Pharma’s Phase 1/2 study
→: First patients enrolled in Atlas Molecular Pharma’s Phase 1/2 studyWe are proud to announce a major step forward in the development of ATL-001, our oral candidate for the treatment of Congenital Erythropoietic Porphyria: the first three patients with CEP…
-
Atlas Molecular Pharma supporting the International Porphyrias Symposium 2025
→: Atlas Molecular Pharma supporting the International Porphyrias Symposium 2025We had the pleasure of supporting the International Porphyrias Symposium 2025 as a Sponsor. The event, held in Washington, DC from October 9 to 12 and organized by the United Porphyrias…
-
Susana Castel joins Atlas Molecular Pharma as CEO
→: Susana Castel joins Atlas Molecular Pharma as CEOSusana Castel has joined Atlas Molecular Pharma as CEO. She brings over 20 years of executive experience in biotech and life sciences, with a focus on strategy and business development. Her…
In the Press
The following coverage reports on the €3 million financing round, led by Inveready, that funds ATL-001’s Phase 1/2 trial in CEP.
- Emprendedores – Expansión Inveready invierte en Atlas Molecular para avanzar en el tratamiento de enfermedades raras January 2026
- Webcapitalriesgo Atlas Molecular Pharma cierra una ronda de €3M liderada por Inveready para avanzar su programa clínico en enfermedades raras January 2026
- Kereon Partners Atlas Molecular – enero 2026 January 2026